ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in
Parkinson's disease patients following four weeks of dosing.
The secondary objectives of the study include the evaluation of the efficacy of ADX48621
compared with placebo in reducing levodopa induced dyskinesia in patients with Parkinson's;
the evaluation of the effect of ADX48621 on symptoms of Parkinson's disease and patient
ability to function, and the evaluation of the effect of coadministration of ADX48621 on
L-dopa efficacy.